Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -406.60K | -4.44M | -4.44M | -4.44M | -4.98M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 34.60K | 182.90K | 184.20K | 195.00K | 784.90K |
| Total Other Non-Cash Items | 26.40K | 3.88M | 3.88M | 3.89M | 3.81M |
| Change in Net Operating Assets | 279.20K | 327.20K | 371.10K | 156.10K | 194.30K |
| Cash from Operations | -66.40K | -54.40K | -8.50K | -205.70K | -195.10K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 98.00K | 80.00K | 110.00K | 280.00K | 280.00K |
| Total Debt Repaid | -32.30K | -53.90K | -65.80K | -82.30K | -110.80K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 65.70K | 26.10K | 44.20K | 197.70K | 169.20K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -800.00 | -28.30K | 35.70K | -8.00K | -25.90K |
